Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Greg22 who wrote (22517)	9/26/1999 7:19:00 PM
From: Frostman	Respond to of 23519

I simply want another profitable quarter with a reasonable amount of the gravy having resulted from sales. sigh Frostman

To: Greg22 who wrote (22517)	9/26/1999 8:07:00 PM
From: E_K_S	Read Replies (1) \| Respond to of 23519

Hi Greg22- What is the chance of a buy out or merger with ALZA (who was recently acquired by Abbott Laboratories). I understand that a majority of the VIVUS sales group was recently (w/i the last year) laid off and moved over to ALZA. It seems to me that a great U.S. marketing partner would be Abbott Laboratories. I would see this (possible) merger as a two step process. First, Abbott would be selected as the U.S representative for both MUSE and Alibra. If that worked out well, then Abbott could take both MUSE and Alibra world wide by acquiring VVUS. The only problem with this thought is that VVUS continues to enter into "other" international agreements with partners that muddy the international channel distributions for MUSE and perhaps for Alibra too. You state that "...Vivus is making the right choice to continue to market Muse themselves..." BUT IMO it still provides for VVUS the option to hook up with a potential merger candidate. The only problem is that as VVUS enters into other "exclusive" distribution agreements, it eliminates the potential for a buy out or merger from large drug companies such as Abbott. EKS